Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Let's Talk Breast Density; Cancer, Movies, and Music; Treatment-Induced Aging?

2.

Many Americans unaware of links between HPV and cancers, poll reveals

3.

AI Unlocks Benefits of Prostate Cancer Treatment.

4.

In 18 States, alcohol exclusion laws are still in effect.

5.

New imaging technique identifies glioblastoma patients who would benefit from immunotherapy


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot